• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Recent advances in targeted therapy of human myelogenous leukaemia.
【24h】

Recent advances in targeted therapy of human myelogenous leukaemia.

机译：人骨髓性白血病靶向治疗的最新进展。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Despite major advances in the diagnosis and treatment of myelogenous leukaemia during the past few decades, this group of diseases remains a serious medical concern with > 15,000 new cases each year and a mortality rate of approximately 10,000 in the US alone. Current available conventional therapies, including chemotherapy and bone marrow transplantation, often cause severe side effects owing mainly to the lack of specificity of the treatment. In the past years, significant progress has been made towards understanding the pathogenesis of myelogenous leukaemia from the molecular standpoint. To this end, a growing number of approaches are being exploited for the identification and validation of new therapeutic targets suitable for more potent and specific or 'targeted' intervention. In this review, the authors focus their discussion on the four most promising myelogenous leukaemia-associated molecular targets currently being pursued by major pharmaceutical and biotechnology companies, fms-like tyrosine kinase 3 (FLT3), CD33, farnesyl transferase and BCR-Abl, with emphasis on recent progress on the clinical development of therapeutic agents, including both kinase inhibitors and monoclonal antibodies, to these targets.
机译：尽管在过去的几十年中，骨髓性白血病的诊断和治疗取得了重大进展，但这一类疾病仍然是严重的医学问题，每年有15,000多例新病例，仅在美国，死亡率就约为10,000。当前可用的常规疗法，包括化学疗法和骨髓移植，通常主要由于缺乏治疗特异性而引起严重的副作用。在过去的几年中，从分子的角度在理解骨髓性白血病的发病机理方面已经取得了重大进展。为此，越来越多的方法被用于鉴定和验证适用于更有效和更具体或“靶向”干预的新治疗靶标。在这篇综述中，作者将讨论集中在主要制药和生物技术公司目前正在寻求的四个最有希望的骨髓性白血病相关分子靶标，fms样酪氨酸激酶3（FLT3），CD33，法呢基转移酶和BCR-Abl以及重点介绍针对这些目标的治疗药物（包括激酶抑制剂和单克隆抗体）的临床开发的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号